Verastem Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment
The company primarily concentrates on discovering and advancing targeted treatments that address the unmet needs of patients with various types of cancers, particularly those that are known to be difficult to treat. Through its research and development efforts, Verastem aims to provide potentially life-changing treatment options for patients and improve outcomes in cancer care. The company works collaboratively with healthcare professionals and researchers to bring its therapies from concept to market, striving to enhance the quality of life for individuals affected by cancer.
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant ovarian cancer is underway.
